More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in
the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor …

An activating mutation of Fms-like tyrosine kinase 3 (FLT3) is the most frequent genetic
alteration associated with poor prognosis in acute myeloid leukemia (AML). Although many …

FLT3/ITD acute myeloid leukemia is a poor prognosis disease driven by a constitutively
activated receptor tyrosine kinase, making it an obvious target for drug development. The …

Fms-like tyrosine kinase 3 (FLT3) is one of the most commonly mutated genes in acute
myeloid leukemia (AML) and as such has been a highly studied therapeutic target in the …

Activating mutations in the receptor tyrosine kinase FLT3 are present in up to approximately
30% of acute myeloid leukemia (AML) patients, implicating FLT3 as a driver of the disease …

Acute myeloid leukemia (AML) is a clonal hematologic neoplasm characterized by rapid,
uncontrolled cell growth of immature myeloid cells (blasts). There are numerous genetic …

FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in AML. Thirty percent
of patients with acute myeloid leukemia (AML) harbor activating mutations in FLT3, either …

Fms-like tyrosine kinase 3 (FLT3) is implicated in the pathogenesis of acute myeloid
leukemia (AML). FLT3-activating internal tandem duplication (ITD) mutations are found in …

Mutations of the type III receptor tyrosine kinase FLT3 occur in approximately 30% of acute
myeloid leukemia patients and lead to constitutive activation. This has made FLT3-activating …

Introduction: Approximately one-third of the patients with acute myeloid leukemia (AML)
harbor internal tandem duplication (ITD) in the gene encoding FMS-like tyrosine kinase 3 …